Treatment of Hepatitis C in Decompensated Cirrhosis Improves Survival
Yes, antiviral therapy with direct-acting antivirals (DAAs) in patients with hepatitis C-related decompensated cirrhosis significantly improves life expectancy and should be initiated urgently in appropriate candidates.
Who Should Be Treated
Patients with decompensated cirrhosis (Child-Pugh B or C up to 12 points) without concomitant comorbidities that could impact survival should be treated urgently 1. This represents a strong A1 recommendation from EASL guidelines.
Key Decision Points:
- MELD Score <18-20: Treat before transplantation 1
- MELD Score ≥18-20: Transplant first, then treat post-transplant, UNLESS waiting time exceeds 6 months 1
- Not transplant candidates: Treat urgently if Child-Pugh ≤12 points 1
Evidence for Survival Benefit
The most recent high-quality evidence demonstrates substantial mortality reduction:
- 5-year transplant-free survival of 74.7% in treated patients with decompensated cirrhosis 2
- 2-year survival of 91.3% with DAA therapy versus 67.6% in untreated controls 3
- Significantly reduced decompensation events: 14.5% at 2 years with treatment versus 53.1% without treatment 3
A large prospective cohort study showed that among 1,152 patients with decompensated cirrhosis, SVR was achieved in 90.8%, with recompensation occurring in 24.7% of patients 4. Importantly, mortality was significantly lower in treated versus untreated patients (28.9 vs. 11.4 months survival) 5.
Treatment Regimens by Genotype
For Genotypes 1,4,5, or 6:
- Sofosbuvir/ledipasvir + ribavirin for 12 weeks (A1) 1
- Sofosbuvir/velpatasvir + ribavirin for 12 weeks (A1) 1
- Sofosbuvir/daclatasvir + ribavirin for 12 weeks (A1) 1
For Genotype 2:
- Sofosbuvir/velpatasvir + ribavirin for 12 weeks (A1) 1
- Sofosbuvir/daclatasvir + ribavirin for 12 weeks (A1) 1
For Genotype 3:
- Sofosbuvir/velpatasvir + ribavirin for 24 weeks (A1) 1
- Sofosbuvir/daclatasvir + ribavirin for 24 weeks (A1) 1
Ribavirin Dosing:
Start at 600 mg daily and increase as tolerated to weight-based dosing (1,000 mg if <75 kg, 1,200 mg if ≥75 kg) 1. For ribavirin-intolerant patients, extend treatment to 24 weeks without ribavirin 1.
Critical Safety Considerations
NEVER use protease inhibitors (paritaprevir, grazoprevir, asunaprevir, glecaprevir) in Child-Pugh B or C patients - this is an absolute contraindication due to drug toxicity from increased concentrations 1, 6, 1.
Expected Outcomes Beyond Survival
Liver Function Improvement:
- One-third to one-half of patients show significant improvements in bilirubin, albumin, INR, and Child-Pugh/MELD scores 1
- Child-Pugh class improvement occurs primarily within the first year, with a significant breakpoint between 24 weeks and 1 year after treatment 2
- 40-49% of patients achieve Child-Pugh A status by 1-3 years post-treatment 2
Important Limitations:
Patients with baseline MELD ≥20 are unlikely to improve liver function significantly 6. Child-Pugh B patients benefit more than Child-Pugh C patients in terms of adverse event-free survival 1.
Monitoring Requirements
Frequent clinical and laboratory assessment is mandatory due to limited safety data in this population 1. Monitor for:
- Hepatic decompensation events (20% may still occur despite treatment) 7
- Hepatocellular carcinoma (develops in 2.9-10% despite SVR) 4, 5
- Sepsis and hospitalizations 8
The Point of No Return
There appears to be a threshold beyond which antiviral therapy cannot reverse liver dysfunction. Patients with Child-Pugh C scores ≥13 or severe decompensation have limited data supporting benefit 6. These patients should be referred to transplant centers for individualized assessment 6.
Bottom Line Algorithm
- Assess MELD score and Child-Pugh class
- If MELD <18-20: Treat immediately with genotype-appropriate DAA + ribavirin
- If MELD ≥18-20 and transplant candidate: Transplant first unless wait time >6 months
- If not transplant candidate and Child-Pugh ≤12: Treat urgently
- Avoid all protease inhibitors
- Monitor closely for decompensation and HCC despite SVR
The evidence unequivocally supports that DAA therapy improves survival and reduces decompensation events in appropriately selected patients with hepatitis C-related decompensated cirrhosis, though the risk of HCC persists even after viral clearance.